The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to &amp;lt; 100 × 109/L) at Baseline

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 109/L to &lt; 100 × 109/L) at Baseline

Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Heinz Gisslinger(Medical University of Vienna), Minghui Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Dietger Niederwieser(Leipzig University of Applied Sciences), Fiorenza Barraco(Hôpital Lyon Sud), Françoise Boyer‐Perrard(Centre Hospitalier Universitaire d'Angers), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Monika Wroclawska(Novartis (Switzerland)), Pantelia Roussou(Novartis (Switzerland)), Anna Marina Liberati(University of Perugia), Kevin Majidi(Novartis (Switzerland)), Srđan Verstovšek(Unknown), Ling Pan(Sichuan University), Peter A. te Boekhorst(Erasmus MC), Jean‐Jacques Kiladjian(Délégation Paris 5), Haitao Meng(First Affiliated Hospital Zhejiang University), Guangsheng He(Jiangsu Province Hospital)

Blood

November 4, 2020

Cited by 7